	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30

Period length: Source:	12M AR	12M AR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	178	233	292	516	600	709	1,483	1,656	1,831	2,080	2,396	2,550
Cost of Operating Revenue	135	171	204	354	390	485	1,153	1,234	1,354	1,500	1,748	1,875
Gross Profit	43	63	88	162	210	224	330	422	477	580	649	675
Gross Margin	24.2	26.8	30.1	31.5	35.0	31.6	22.2	25.5	26.0	27.9	27.1	26.5
Total Operating Expenses	170	213	255	451	512	609	1,348	1,496	1,648	1,893	2,206	2,338
Operating Profit	8	20	38	66	88	100	135	160	183	187	190	212
Operating Margin	4.4	8.7	12.9	12.7	14.7	14.1	9.1	9.7	10.0	9.0	7.9	8.3
Financing Income/(Expense) - Net	-3	-2	0	-2	0	4	-9	-20	-10	-6	-10	-34
Profit before Taxes	5	19	37	63	88	107	136	144	178	185	203	204
Income Taxes	1	5	12	18	23	27	39	37	47	49	53	53
Profit after Tax	3	14	25	46	65	80	98	107	131	136	149	151
PAT Margin	1.9	6.0	8.7	8.8	10.9	11.3	6.6	6.5	7.1	6.6	6.2	5.9
EPS - Basic - ex Extraordinary Items	0.67	2.76	5.01	9.00	12.86	15.56	17.81	19.46	23.67	24.66	26.95	27.22
EPS - Diluted - ex Extraordinary Items	0.67	2.76	5.01	9.00	12.86	15.47	17.70	19.38	23.62	24.63	26.93	27.20
EBIT	8	20	38	66	88	100	135	160	183	187	190	212
EBITDA	12	24	43	78	105	123	183	223	243	254	269	299
EBITDA Margin	6.9	10.5	14.6	15.1	17.5	17.3	12.4	13.5	13.3	12.2	11.2	11.7

Balance Sheet

Abridged

Understanding Balance Sheet

Rossari Biotech Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	PR	PR	PR	AR	AR	AR	AR	AR	AR
Total Current Assets	59	75	110	160	326	355	609	721	845	1,043	1,244
Long-Term Investments	0	0	0	0	5	20	0	0	0	0	1
Property Plant & Equipment - Net	43	45	53	78	111	168	348	327	362	494	734
Total Non-Current Assets	45	46	55	90	145	207	647	646	727	853	1,045
Total Assets	104	122	165	250	472	561	1,257	1,368	1,572	1,896	2,289
Total Current Liabilities	52	56	73	122	149	150	295	349	425	537	790
Long Term Debt	7	2	1	1	34	-	85	35	44	122	115
Total Non-Current Liabilities	7	5	5	4	36	2	157	104	100	174	166
Total Liabilities	59	61	78	126	185	153	452	452	524	711	955
Total Shareholders' Equity	45	61	87	124	287	409	805	915	1,048	1,185	1,333
Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Total Equity	45	61	87	124	287	409	805	915	1,048	1,185	1,333
Total Liabilities & Equity	104	122	165	250	472	561	1,257	1,368	1,572	1,896	2,289

Cash Flow

Abridged

Understanding Cash Flow Statement

Rossari Biotech Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	7.65	19.59	34.79	58.23	86.09	95.70	145.17	175.55	186.82	194.63	195.25
Working Capital - Increase/(Decrease)	12.16	-15.38	-9.91	11.39	-31.07	-48.30	-112.99	-27.83	-156.85	-72.98	-153.85
Net CF from Operating Activities	19.81	4.21	24.87	69.62	55.03	47.40	32.18	147.72	29.97	121.66	41.39
Capital Expenditures - Net	4.65	5.54	13.93	43.99	75.89	55.90	36.31	31.19	125.79	158.49	240.50
Net CF from Investing Activities	-4.65	-5.54	-21.10	-37.00	-191.80	-40.71	-303.85	-183.16	-105.92	-184.42	-220.97
Dividends Paid - Cash - Total	-	-	0.27	10.59	2.65	2.54	2.75	2.75	2.76	2.76	2.77
Stock - Issuance/(Retirement) - Net	-	-	-	-	100.00	42.65	301.50	4.21	3.85	5.07	0.83
Debt - LT & ST - Issuance/(Retirement) - Total	-14.10	1.66	-4.87	-16.42	62.89	-61.01	-4.81	65.50	31.09	79.12	213.42
Net Cash Flow from Financing Activities	-14.10	1.09	-5.14	-27.01	160.24	-20.70	293.94	66.96	32.17	81.42	211.48
Free Cash Flow to Equity	1.06	0.33	6.08	9.21	42.03	-69.51	-8.95	182.03	-64.73	42.28	14.31
Free Operating CF net dividend	15.16	-1.33	10.68	15.04	-23.59	-13.22	-8.80	112.09	-104.07	-39.62	-226.04
Free Operating CF	15.16	-1.33	10.95	25.63	-20.95	-10.68	-6.05	114.84	-101.31	-36.86	-223.28

Business Segment Analysis

FY End:

Mar 26

Rossari Biotech Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Specialty Chemicals for textile and personal care (100.0%)₹ 264.67 Cr

Revenue / Sales

Specialty Chemicals for textile and personal care (100.0%)₹ 2,396.37 Cr

Assets

Specialty Chemicals for textile and personal care (100.0%)₹ 2,288.79 Cr

Operating Income

Specialty Chemicals for textile and personal care (100.0%)₹ 189.93 Cr

Regional Segment Analysis

FY End:

Mar 26

Rossari Biotech Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (74.4%)₹ 1,782.81 CrOutside India (25.6%)₹ 613.55 Cr

Historical Segment Analysis

Track how Rossari Biotech Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Specialty Chemicals for textile and personal care	58	38	33	131	159	265

Frequently Asked Questions

What is the revenue of Rossari Biotech Ltd.?

The latest trailing twelve month revenue of Rossari Biotech Ltd. is ₹ 2,549.85 Cr, reflecting a 1-year growth of 19.47% and a 3-year CAGR of 16.04%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Rossari Biotech Ltd.?

The latest trailing twelve month net profit (PAT) of Rossari Biotech Ltd. is ₹ 150.71 Cr, with a 3-year earnings CAGR of 11.79%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Rossari Biotech Ltd.?

The trailing twelve month EBITDA of Rossari Biotech Ltd. is approximately ₹ 211.68 Cr (based on an operating margin of 8.30%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Rossari Biotech Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Rossari Biotech Ltd. is 27.20. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Rossari Biotech Ltd.?

The debt-to-equity ratio of Rossari Biotech Ltd. stands at 0.33. The interest coverage ratio is 6.26x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Rossari Biotech Ltd.?

The estimated book value per share of Rossari Biotech Ltd. is 240.70 (derived from a P/B ratio of 2.19 and market price of ₹ 528.20), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Rossari Biotech Ltd.?

The trailing twelve month operating cash flow of Rossari Biotech Ltd. is ₹ 41.40 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Rossari Biotech Ltd. report consolidated or standalone financials?

Rossari Biotech Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.